-
Je něco špatně v tomto záznamu ?
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
G. Comi, L. Kappos, KW. Selmaj, A. Bar-Or, DL. Arnold, L. Steinman, HP. Hartung, X. Montalban, E. Kubala Havrdová, BAC. Cree, JK. Sheffield, N. Minton, K. Raghupathi, N. Ding, JA. Cohen, SUNBEAM Study Investigators,
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2002-05-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest)
od 2002-05-01 do Před 2 měsíci
- MeSH
- atrioventrikulární blokáda chemicky indukované MeSH
- bradykardie chemicky indukované MeSH
- dospělí MeSH
- imunosupresiva škodlivé účinky terapeutické užití MeSH
- indany škodlivé účinky terapeutické užití MeSH
- interferon beta 1a škodlivé účinky terapeutické užití MeSH
- kognitivní poruchy etiologie MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozek patologie MeSH
- neurozobrazování MeSH
- oxadiazoly škodlivé účinky terapeutické užití MeSH
- progrese nemoci MeSH
- receptory sfingosin-1-fosfátu antagonisté a inhibitory MeSH
- relabující-remitující roztroušená skleróza farmakoterapie patologie psychologie MeSH
- šedá hmota patologie MeSH
- stupeň závažnosti nemoci MeSH
- velikost orgánu MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis. METHODS: SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries. We enrolled participants aged 18-55 years with relapsing multiple sclerosis, baseline expanded disability status scale (EDSS) score of 0·0-5·0, and either at least one relapse within the 12 months before screening or at least one relapse within 24 months plus at least one gadolinium-enhancing lesion within 12 months before screening. Participants were randomly assigned 1:1:1 by a blocked algorithm stratified by country and baseline EDSS score to at least 12 months treatment of either once-daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment assignment. The primary endpoint was annualised relapse rate (ARR) during the treatment period and was assessed in the intention-to-treat population. Safety was assessed in all participants according to the highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, number NCT02294058 and EudraCT, number 2014-002320-27. FINDINGS: Between Dec 18, 2014, and Nov 12, 2015, 1346 participants were enrolled and randomly assigned to ozanimod 1·0 mg (n=447), ozanimod 0·5 mg (n=451), or interferon beta-1a (n=448). 91 (6·8%) participants discontinued the study drug (29 in the ozanimod 1·0 mg group; 26 in the ozanimod 0·5 mg group; and 36 in the interferon beta-1a group). Adjusted ARRs were 0·35 (0·28-0·44) for interferon beta-1a, 0·18 (95% CI 0·14-0·24) for ozanimod 1·0 mg (rate ratio [RR] of 0·52 [0·41-0·66] vs interferon beta-1a; p<0·0001), and 0·24 (0·19-0·31) for ozanimod 0·5 mg (RR 0·69 [0·55-0·86] vs interferon beta-1a; p=0·0013). Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2·9%] who received ozanimod 1·0 mg; seven [1·5%] who received ozanimod 0·5 mg; and 16 [3·6%] who received interferon beta-1a). No first-dose, clinically significant bradycardia or second-degree or third-degree atrioventricular block was reported. The incidence of serious adverse events was low and similar across treatment groups (13 [2·9%] participants who received ozanimod 1·0 mg; 16 [3·5%] who received ozanimod 0·5 mg; and 11 [2·5%] who received interferon beta-1a). No serious opportunistic infections occurred in ozanimod-treated participants. INTERPRETATION: In participants with relapsing multiple sclerosis treated for at least 12 months, ozanimod was well tolerated and demonstrated a significantly lower relapse rate than interferon beta-1a. These findings provide support for ozanimod as an oral therapy for individuals with relapsing multiple sclerosis. FUNDING: Celgene International II.
Center for Neurology Lodz Poland
Collegium Medicum Department of Neurology University of Warmia and Mazury Olsztyn Poland
Department of Biostatistics Celgene Corporation Summit NJ USA
Department of Clinical Development Celgene Corporation Summit NJ USA
Department of Neurology Medical Faculty Heinrich Heine University Dusseldorf Germany
Division of Neurology St Michael's Hospital University of Toronto Toronto ON Canada
Drug Safety Celgene Corporation Summit NJ USA
Mellen Center for Multiple Sclerosis Treatment and Research Cleveland Clinic Cleveland OH USA
Neurologic Clinic and Policlinic University Hospital and University of Basel Basel Switzerland
NeuroRx Research and Montreal Neurological Institute McGill University Montreal QC Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023542
- 003
- CZ-PrNML
- 005
- 20201214130337.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1474-4422(19)30239-X $2 doi
- 035 __
- $a (PubMed)31492651
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Comi, Giancarlo $u Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: comi.giancarlo@hsr.it.
- 245 10
- $a Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial / $c G. Comi, L. Kappos, KW. Selmaj, A. Bar-Or, DL. Arnold, L. Steinman, HP. Hartung, X. Montalban, E. Kubala Havrdová, BAC. Cree, JK. Sheffield, N. Minton, K. Raghupathi, N. Ding, JA. Cohen, SUNBEAM Study Investigators,
- 520 9_
- $a BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis. METHODS: SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries. We enrolled participants aged 18-55 years with relapsing multiple sclerosis, baseline expanded disability status scale (EDSS) score of 0·0-5·0, and either at least one relapse within the 12 months before screening or at least one relapse within 24 months plus at least one gadolinium-enhancing lesion within 12 months before screening. Participants were randomly assigned 1:1:1 by a blocked algorithm stratified by country and baseline EDSS score to at least 12 months treatment of either once-daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment assignment. The primary endpoint was annualised relapse rate (ARR) during the treatment period and was assessed in the intention-to-treat population. Safety was assessed in all participants according to the highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, number NCT02294058 and EudraCT, number 2014-002320-27. FINDINGS: Between Dec 18, 2014, and Nov 12, 2015, 1346 participants were enrolled and randomly assigned to ozanimod 1·0 mg (n=447), ozanimod 0·5 mg (n=451), or interferon beta-1a (n=448). 91 (6·8%) participants discontinued the study drug (29 in the ozanimod 1·0 mg group; 26 in the ozanimod 0·5 mg group; and 36 in the interferon beta-1a group). Adjusted ARRs were 0·35 (0·28-0·44) for interferon beta-1a, 0·18 (95% CI 0·14-0·24) for ozanimod 1·0 mg (rate ratio [RR] of 0·52 [0·41-0·66] vs interferon beta-1a; p<0·0001), and 0·24 (0·19-0·31) for ozanimod 0·5 mg (RR 0·69 [0·55-0·86] vs interferon beta-1a; p=0·0013). Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2·9%] who received ozanimod 1·0 mg; seven [1·5%] who received ozanimod 0·5 mg; and 16 [3·6%] who received interferon beta-1a). No first-dose, clinically significant bradycardia or second-degree or third-degree atrioventricular block was reported. The incidence of serious adverse events was low and similar across treatment groups (13 [2·9%] participants who received ozanimod 1·0 mg; 16 [3·5%] who received ozanimod 0·5 mg; and 11 [2·5%] who received interferon beta-1a). No serious opportunistic infections occurred in ozanimod-treated participants. INTERPRETATION: In participants with relapsing multiple sclerosis treated for at least 12 months, ozanimod was well tolerated and demonstrated a significantly lower relapse rate than interferon beta-1a. These findings provide support for ozanimod as an oral therapy for individuals with relapsing multiple sclerosis. FUNDING: Celgene International II.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a atrioventrikulární blokáda $x chemicky indukované $7 D054537
- 650 _2
- $a bradykardie $x chemicky indukované $7 D001919
- 650 _2
- $a mozek $x patologie $7 D001921
- 650 _2
- $a kognitivní poruchy $x etiologie $7 D003072
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a šedá hmota $x patologie $7 D066128
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x škodlivé účinky $x terapeutické užití $7 D007166
- 650 _2
- $a indany $x škodlivé účinky $x terapeutické užití $7 D007189
- 650 _2
- $a interferon beta 1a $x škodlivé účinky $x terapeutické užití $7 D000068556
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x patologie $x psychologie $7 D020529
- 650 _2
- $a neurozobrazování $7 D059906
- 650 _2
- $a velikost orgánu $7 D009929
- 650 _2
- $a oxadiazoly $x škodlivé účinky $x terapeutické užití $7 D010069
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a receptory sfingosin-1-fosfátu $x antagonisté a inhibitory $7 D000081025
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kappos, Ludwig $u Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland.
- 700 1_
- $a Selmaj, Krzysztof W $u Center for Neurology, Lodz, Poland; Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland.
- 700 1_
- $a Bar-Or, Amit $u Center for Neuroinflammation and Experimental Therapeutics, and Multiple Sclerosis Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- 700 1_
- $a Arnold, Douglas L $u NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
- 700 1_
- $a Steinman, Lawrence $u Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA.
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany.
- 700 1_
- $a Montalban, Xavier $u Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a Kubala Havrdová, Eva $u Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Cree, Bruce A C $u Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
- 700 1_
- $a Sheffield, James K $u Department of Clinical Development, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Minton, Neil $u Drug Safety, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Raghupathi, Kartik $u Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Ding, Ning $u Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Cohen, Jeffrey A $u Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
- 710 2_
- $a SUNBEAM Study Investigators
- 773 0_
- $w MED00006921 $t The Lancet. Neurology $x 1474-4465 $g Roč. 18, č. 11 (2019), s. 1009-1020
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31492651 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130335 $b ABA008
- 999 __
- $a ok $b bmc $g 1595861 $s 1114218
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 18 $c 11 $d 1009-1020 $e 20190903 $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
- LZP __
- $a Pubmed-20201125
